Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 May 1;37(6):957-966.
doi: 10.1097/QAD.0000000000003494. Epub 2023 Jan 25.

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition

Virginia A Fonner  1 , Kathleen Ridgeway  1 , Ariane van der Straten  2 , Lara Lorenzetti  1 , Nhi Dinh  1 , Michelle Rodolph  3 , Robin Schaefer  3 , Heather-Marie A Schmidt  3   4 , Van Thi Thuy Nguyen  5 , Mopo Radebe  6 , Hortencia Peralta  7 , Rachel Baggaley  3
Affiliations
Meta-Analysis

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition

Virginia A Fonner et al. AIDS. .

Abstract

Objective: HIV remains a significant burden, despite expanding HIV prevention tools. Long-acting injectable cabotegravir (CAB-LA) is a new preexposure prophylaxis (PrEP) product. We reviewed existing evidence to determine the efficacy and safety of CAB-LA as PrEP to inform global guidelines.

Design: Systematic review and meta-analysis.

Methods: We systematically reviewed electronic databases and conference abstracts for citations on CAB-LA from January 2010 to September 2021. Outcomes included HIV infection, adverse events, drug resistance, pregnancy-related adverse events, and sexual behavior. We calculated pooled effect estimates using random-effects meta-analysis and summarized other results narratively.

Results: We identified 12 articles/abstracts representing four multisite randomized controlled trials. Study populations included cisgender men, cisgender women, and transgender women. The pooled relative risk of HIV acquisition comparing CAB-LA to oral PrEP within efficacy studies was 0.21 (95% confidence interval: 0.07-0.61), resulting in a 79% reduction in HIV risk. Rates of adverse events were similar across study groups. Of 19 HIV infections among those randomized to CAB-LA with results available, seven had integrase strand transfer inhibitor (INSTI) resistance. Data on pregnancy-related adverse events were sparse. No studies reported on sexual behavior.

Conclusions: CAB-LA is highly efficacious for HIV prevention with few safety concerns. CAB-LA may lead to an increased risk of INSTI resistance among those who have acute HIV infection at initiation or become infected while taking CAB-LA. However, results are limited to controlled studies; more research is needed on real-world implementation. Additional data are needed on the safety of CAB-LA during pregnancy (for mothers and infants) and among populations not included in the trials.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Fig. 1
Fig. 1
Study selection process.
Fig. 2
Fig. 2
Forest plots for synthesized effect sizes within the efficacy studies.
See this image and copyright information in PMC

References

    1. UNAIDS. Global HIV & AIDS statistics — fact sheet. Geneva: UNAIDS; 2022. Available at: https://www.unaids.org/en/resources/fact-sheet.
    1. World Health Organization, World Health Organization. Guideline on when to start antiretroviral therapy and on preexposure prophylaxis for HIV. 2015. - PubMed
    1. World Health Organization. What's the 2+1+1? Event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men: update to WHO's recommendation on oral PrEP. Geneva: WHO; 2019.
    1. World Health Organization. Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Geneva: WHO; 2021. - PubMed
    1. Celum C, Baeten J. PrEP for HIV prevention: evidence, global scale-up, and emerging options. Cell Host Microbe 2020; 27:502–506. - PubMed

Publication types

LinkOut - more resources